BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 21856081)

  • 21. [Breast cancer chemoprevention. Rational, trials results and future].
    Cutuli B; Lesur A; Namer M; Kerbrat P
    Bull Cancer; 2009 May; 96(5):519-30. PubMed ID: 19467983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast cancer risk management.
    Reeder JG; Vogel VG
    Clin Breast Cancer; 2007 Dec; 7(11):833-40. PubMed ID: 18269772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy.
    Labrie F
    Nat Clin Pract Endocrinol Metab; 2007 Aug; 3(8):584-93. PubMed ID: 17643129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New approaches to the endocrine prevention and treatment of breast cancer.
    Howell A; Howell SJ; Evans DG
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S39-44. PubMed ID: 12819938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
    Tang SC
    Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
    Lee WL; Cheng MH; Chao HT; Wang PH
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):24-31. PubMed ID: 18400579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG
    Ann N Y Acad Sci; 2006 Nov; 1089():127-42. PubMed ID: 17261762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemoprevention of breast cancer.
    O'Regan RM
    Lancet; 2006 Apr; 367(9520):1382-3. PubMed ID: 16650636
    [No Abstract]   [Full Text] [Related]  

  • 29. The STAR (Study of Tamoxifen and Raloxifene) trial in West Virginia.
    Jubelirer SJ; Crowell EB
    W V Med J; 2000; 96(6):602-4. PubMed ID: 11194089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemoprevention in postmenopausal women.
    Rastogi P
    Menopause; 2008; 15(4 Suppl):810-5. PubMed ID: 18596603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast cancer prevention by antihormones and other drugs: where do we stand?
    Lazzeroni M; DeCensi A
    Hematol Oncol Clin North Am; 2013 Aug; 27(4):657-72, vii. PubMed ID: 23915737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current concepts in breast cancer chemoprevention.
    Chlebowski RT
    Pol Arch Med Wewn; 2014; 124(4):191-9. PubMed ID: 24618912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
    Chlebowski RT; Col N; Winer EP; Collyar DE; Cummings SR; Vogel VG; Burstein HJ; Eisen A; Lipkus I; Pfister DG;
    J Clin Oncol; 2002 Aug; 20(15):3328-43. PubMed ID: 12149307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
    Reimers LL; Sivasubramanian PS; Hershman D; Terry MB; Greenlee H; Campbell J; Kalinsky K; Maurer M; Jayasena R; Sandoval R; Alvarez M; Crew KD
    Breast J; 2015; 21(4):377-86. PubMed ID: 25879521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular effects of aromatase inhibitors: data from clinical trials.
    Howell A; Cuzick J
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):143-9. PubMed ID: 15936188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoprevention of breast cancer.
    Thomsen A; Kolesar JM
    Am J Health Syst Pharm; 2008 Dec; 65(23):2221-8. PubMed ID: 19020189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond.
    Bao T; Prowell T; Stearns V
    Am J Ther; 2006; 13(4):337-48. PubMed ID: 16858170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Fu R; Zakher B; Pappas M; McDonagh M
    JAMA; 2019 Sep; 322(9):868-886. PubMed ID: 31479143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
    Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
    Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.